-
Validating Astrocyte-produced Protein GDF15 as a Novel Neuroprotective Therapy
… of rescuing both SN and VTA dopamine-producing cells from death in an in vitro model of PD. GDF15, therefore, is … evaluate the ability of GDF15 to protect their brain cells from death. Next, we will confirm the therapeutic potential …
-
Does the Brain's Ability to Compensate for the Shortage of Dopamine Affect Parkinson's Disease Progression?
… the scans at two time points with an interval of two years from 325 people with PD. All study participants will perform … shift in research, re-orienting therapeutic clinical trials from neuroprotection to neuroplasticity. …
-
Patient-Carer-Provider Communication about the Impact of Motor and Non-motor Fluctuations
… and care partners. We shall use the information gathered from the first phase to guide the second phase, in which we … about the impact and communication of OFF periods from a larger sample of each of the above groups of people. …
-
Development of Experimental Setups Using New Antibodies to Detect Alpha-synuclein in Cerebrospinal Fluid
… antibodies will be evaluated using brain biosamples from people with synucleinopathies (PD and Lewy Body … assay prototype(s) will be evaluated using biosamples from two well-characterized groups of people. If this …
-
Structural Characterization of the GCase/LIMP-2 Complex
… algorithms to calculate a 3D model of this protein complex. From this 3D model, we can then deduce the interface of both … the LIMP-2/GCase complex, we will design peptides derived from the binding interface. These peptides will first be …
-
Expansion of Studies to Develop Tear Biomarkers of Parkinson's Disease
… This grant builds upon the research from a prior grant: Identification of Tear Biomarkers for … healthy people. We will also collect additional information from study participants with PD, which will help us …